Urocortin II, human
Nootropic / cognitive
Cognition, mood, neuroprotection, or neuroplasticity support
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- Nootropic / neuroactive compound
- Primary mechanism
- Neurotransmitter, neurotrophic, or plasticity pathway modulation
- Primary market use
- Nootropic / cognitive
Pharmacology
- Molecular weight (Da)
- 4152.89
- Oral bioavailability
- Route-dependent / verify
- Half-life
- ~5–60 min parent peptide; analogs may be longer
- Route tags
- SubQ; Injectable; route-dependent
- Evidence level
- MCE product listing / research chemical signal
- Clinical status
- Research chemical/reference listing
- Value-for-money score
- 8 / 10
Reported protocol signal
No clean popular protocol found in uploaded sources; create as research/reference entry and verify before public protocol display.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Stackability
Place in nootropic comparison clusters; track acute vs durable cognitive adaptation.
Notes
Urocortin II, human acetate is a selective endogenous peptide agonist of type-2 corticotropin-releasing factor (CRF2) receptor . Urocortin II, human acetate has an effect of promoting satiet and neuroprotective effect. Urocortin II, human acetate also has bactericidal , antiparasitic and pro-inflammation activity. Urocortin II, human acetate can activate NF-κB pathway and ERK1/2 MAP kinase. Urocortin II, human acetate can reduce pulmonary arterial hypertension and shows cardiac protection effect...